MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. BFLY
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Butterfly Network (BFLY) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Butterfly Network
NYSE•Healthcare•Medical Devices
$7.52+0.16(0.02%)Pre-market
Market Cap
$2.09B
P/S
18.6x
P/B
11.0x

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. The company offers Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging on a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; Butterfly Move, merging the mobility of a handheld with the stability of a full cart system; and iQ+ Bladder, a specialty product for bladder scanning market. It also provides Compass AI which offers one system to connect every device, workflow, and department; ScanLab, an AI-powered educational platform that provides written walkthroughs and reference imagery to guide real-time educational scanning; and Butterfly iQ+/iQ3 Vet, a third generation handheld ultrasound system. It sells and markets its products through a direct sales force, distributors, and e-commerce channels. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

D

How this company scores

WeakMetricSide Score: 41/100

Grade capped at D — Interest coverage below 1× (-70.4x) — earnings cannot cover interest. Strongest: Growth (16/25); weakest: Cash & Earnings Quality (7/25).

Profitability11/25
Growth16/25
Balance Sheet & Red Flags7/25
Cash & Earnings Quality7/25
Strengths
Growing revenueLong cash runwayConsistent growthNet cash position
Grade capped at D
  • Interest coverage below 1× (-70.4x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 18.6x5y range 2.5x – 45.9x
P/S 18.6x · above its 20-quarter median

Currently above its 20-quarter median.

P/B · 11.0x5y range 0.9x – 11.0x
P/B 11.0x · above its 20-quarter median

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume
Market Cap $2.09B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$112.14M
7Q
Q. Revenue
$32.61M
39%
TTM EBITDA
$-72.27M
2Q
TTM Op. Income
$-79.38M
3Q
Q. Op. Income
$-13.66M
3Q
TTM Net Income
$-74.85M
3Q
Q. Net Income
$-12.91M
7%
EPS
$-0.05
17%
Shares Out.
$262.10M
7Q
$112.14M in TTM revenue grew 28.1% YoY, reaching $32.61M last quarter. TTM EBITDA of $-72.27M and TTM operating income of $-79.38M show growth is flowing through to the bottom line. However, net income is negative at $74.85M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
71.4%
3Q
EBITDA Margin
-36.8%
3Q
Op. Margin
-41.9%
3Q
Net Margin
-39.6%
3Q
Op. margin of -41.9% is up 27.0% YoY — cost efficiency is improving. Net margin at -39.6% and gross margin of 71.4% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 3 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
N/A
P/S Ratio
18.6x
228%
P/B Ratio
11.0x
4Q
P/S of 18.6x and P/B of 11.0x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$283.00M
2Q
Cash
$124.66M
2Q
Long-Term Debt
N/A
Book Value
$189.40M
5Q
D/E Ratio
N/A
Debt/EBITDA
N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$-16.27M
2Q
TTM Free Cash Flow
$-28.04M
2Q
FCF Margin
-25.0%
2Q
FCF / Net Income
0.4
2Q
TTM FCF of $-28.04M on $-16.27M in operating cash flow. The FCF / Net Income ratio of 0.4x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General

Cash Burn

Red Flag

The last 5 consecutive quarters had negative FCF — the company is burning cash and may need external funding.

Share Dilution

Red Flag

Shares outstanding increased 23.2% — significant dilution, likely from stock compensation or capital raises.